Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

R. M. Silver, J. H. Warrick, M. B. Kinsella, L. S. Staudt, M. H. Baumann, C. Strange

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Fourteen patients with systemic sclerosis (SSc, scleroderma) and interstitial lung disease were treated with oral cyclophosphamide (1-2 mg/kg/day) and low dose prednisone (<10 mg/day). There was a significant improvement in FVC after 6 months compared to entry values (2.21 ± 0.19 l vs 2.03 ± 0.15 l, p < 0.02). Improvement was maintained at 12 months (2.27 ± 0.27 l, p < 0.05) and 18-24 months (2.60 + 0.28 l, p < 0.001). In 12 cases followed for 18-24 months, FVC was stable or improved. No significant improvement or decline was noted for the DLCO. Side effects included cytopenia (2), infection (1), and hemorrhagic cystitis (2), and one possible related malignancy. A controlled prospective trial of cyclophosphamide is warranted in patients with SSc and active interstitial lung disease.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalJournal of Rheumatology
Volume20
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Systemic Scleroderma
Interstitial Lung Diseases
Prednisone
Cyclophosphamide
Cystitis
Therapeutics
Infection
Neoplasms

Keywords

  • alveolitis
  • cyclophosphamide
  • pulmonary function
  • scleroderma
  • systemic sclerosis
  • treatment

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Silver, R. M., Warrick, J. H., Kinsella, M. B., Staudt, L. S., Baumann, M. H., & Strange, C. (1993). Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. Journal of Rheumatology, 20(5), 838-844.

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. / Silver, R. M.; Warrick, J. H.; Kinsella, M. B.; Staudt, L. S.; Baumann, M. H.; Strange, C.

In: Journal of Rheumatology, Vol. 20, No. 5, 1993, p. 838-844.

Research output: Contribution to journalArticle

Silver, RM, Warrick, JH, Kinsella, MB, Staudt, LS, Baumann, MH & Strange, C 1993, 'Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease', Journal of Rheumatology, vol. 20, no. 5, pp. 838-844.
Silver, R. M. ; Warrick, J. H. ; Kinsella, M. B. ; Staudt, L. S. ; Baumann, M. H. ; Strange, C. / Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. In: Journal of Rheumatology. 1993 ; Vol. 20, No. 5. pp. 838-844.
@article{98fefe60412b486fb03f7f1932b64508,
title = "Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease",
abstract = "Fourteen patients with systemic sclerosis (SSc, scleroderma) and interstitial lung disease were treated with oral cyclophosphamide (1-2 mg/kg/day) and low dose prednisone (<10 mg/day). There was a significant improvement in FVC after 6 months compared to entry values (2.21 ± 0.19 l vs 2.03 ± 0.15 l, p < 0.02). Improvement was maintained at 12 months (2.27 ± 0.27 l, p < 0.05) and 18-24 months (2.60 + 0.28 l, p < 0.001). In 12 cases followed for 18-24 months, FVC was stable or improved. No significant improvement or decline was noted for the DLCO. Side effects included cytopenia (2), infection (1), and hemorrhagic cystitis (2), and one possible related malignancy. A controlled prospective trial of cyclophosphamide is warranted in patients with SSc and active interstitial lung disease.",
keywords = "alveolitis, cyclophosphamide, pulmonary function, scleroderma, systemic sclerosis, treatment",
author = "Silver, {R. M.} and Warrick, {J. H.} and Kinsella, {M. B.} and Staudt, {L. S.} and Baumann, {M. H.} and C. Strange",
year = "1993",
language = "English (US)",
volume = "20",
pages = "838--844",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

AU - Silver, R. M.

AU - Warrick, J. H.

AU - Kinsella, M. B.

AU - Staudt, L. S.

AU - Baumann, M. H.

AU - Strange, C.

PY - 1993

Y1 - 1993

N2 - Fourteen patients with systemic sclerosis (SSc, scleroderma) and interstitial lung disease were treated with oral cyclophosphamide (1-2 mg/kg/day) and low dose prednisone (<10 mg/day). There was a significant improvement in FVC after 6 months compared to entry values (2.21 ± 0.19 l vs 2.03 ± 0.15 l, p < 0.02). Improvement was maintained at 12 months (2.27 ± 0.27 l, p < 0.05) and 18-24 months (2.60 + 0.28 l, p < 0.001). In 12 cases followed for 18-24 months, FVC was stable or improved. No significant improvement or decline was noted for the DLCO. Side effects included cytopenia (2), infection (1), and hemorrhagic cystitis (2), and one possible related malignancy. A controlled prospective trial of cyclophosphamide is warranted in patients with SSc and active interstitial lung disease.

AB - Fourteen patients with systemic sclerosis (SSc, scleroderma) and interstitial lung disease were treated with oral cyclophosphamide (1-2 mg/kg/day) and low dose prednisone (<10 mg/day). There was a significant improvement in FVC after 6 months compared to entry values (2.21 ± 0.19 l vs 2.03 ± 0.15 l, p < 0.02). Improvement was maintained at 12 months (2.27 ± 0.27 l, p < 0.05) and 18-24 months (2.60 + 0.28 l, p < 0.001). In 12 cases followed for 18-24 months, FVC was stable or improved. No significant improvement or decline was noted for the DLCO. Side effects included cytopenia (2), infection (1), and hemorrhagic cystitis (2), and one possible related malignancy. A controlled prospective trial of cyclophosphamide is warranted in patients with SSc and active interstitial lung disease.

KW - alveolitis

KW - cyclophosphamide

KW - pulmonary function

KW - scleroderma

KW - systemic sclerosis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0027314630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027314630&partnerID=8YFLogxK

M3 - Article

C2 - 8336309

AN - SCOPUS:0027314630

VL - 20

SP - 838

EP - 844

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -